Accordingly, the conventional treatment strategy of HF, with modulation of the neurohormonal activation, may not have the same effect in obese patients with HF, and instead, novel treatment strategies should be considered e.g. intended weight loss, mineralocorticoid receptor antagonist, sodium–glucose co-transporter-2 inhibitor, LCZ696. This evidence concerns the gene NR3C2 and hydrops fetalis.